During the past decade, Tucson Clinical Research conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Tucson Clinical Research" are "Diabetes Mellitus, Type 2" (1 trials) and "Diabetes Type 2" (1 trials). Many other conditions were trialed in "Tucson Clinical Research" in a lesser frequency.

Most popular intervention types in "Tucson Clinical Research" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)" (1 trials), "Placebo" (1 trials), "Technosphere® Insulin Inhalation Powder" (1 trials) and "Vildagliptin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tucson Clinical Research" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Tucson Clinical Research". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Tucson Clinical Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tucson Clinical Research, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".